Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Delcath Systems Inc DCTH

Healthcare Medical Devices Diagnostics & Research
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while... see more

Recent & Breaking News (NDAQ:DCTH)

Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

Business Wire May 28, 2024

Delcath Systems Reports First Quarter 2024 Results and Business Highlights

PR Newswire May 14, 2024

Delcath Systems to Host First Quarter 2024 Earnings Call

PR Newswire May 7, 2024

Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT

PR Newswire May 6, 2024

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire May 3, 2024

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire April 4, 2024

Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

PR Newswire March 26, 2024

Delcath Systems Closes $7 Million Private Placement

PR Newswire March 20, 2024

Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call

PR Newswire March 19, 2024

Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

PR Newswire March 18, 2024

Delcath Systems Announces $7 Million Private Placement

PR Newswire March 15, 2024

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire March 8, 2024

Delcath Systems to Participate in Upcoming Investor Conferences

PR Newswire March 8, 2024

Delcath Systems Announces Healthcare Setting Locator for HEPZATO(TM) KIT (melphalan/Hepatic Delivery System)

PR Newswire February 22, 2024

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire February 16, 2024

Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO(TM) (melphalan/Hepatic Delivery System) Effective April 1, 2024

PR Newswire January 31, 2024

Delcath Systems to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

PR Newswire January 23, 2024

Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KIT(TM)

PR Newswire January 16, 2024

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire January 12, 2024

Delcath Systems Announces Publication by Independent Investigators of a Retrospective Analysis of Quality of Life in the Journal Melanoma Research

PR Newswire December 7, 2023